Login to Your Account



'Enormous' Crowds Expected at Meeting

Avandia Briefing Docs Reveal Debate on Drug's CV Safety

By Donna Young


Monday, July 12, 2010
WASHINGTON – Closely guarded briefing documents released by the FDA Friday morning revealed more details about the ongoing internal debate at the agency about whether GlaxoSmithKline plc's Type II diabetes drug Avandia (rosiglitazone) should be removed from the U.S. market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription